IDEXX Laboratories, Inc. — Form 10-Q Summary
Business context and reporting period
IDEXX develops diagnostic and information technology products and services for veterinary markets, water-quality testing, livestock and poultry diagnostics, dairy testing, and human point-of-care diagnostics. The filing covers the quarter and nine months ended September 30, 2011. Results are unaudited and prepared under U.S. GAAP.
The Companion Animal Group (CAG) generated approximately 82% of third-quarter revenue and remained the primary operating segment. Management noted continued economic pressure on veterinary visits and capital purchases, while foreign-currency movements benefited reported revenue.
Key financial metrics
| Metric | Q3 2011 | Q3 2010 | 9M 2011 | 9M 2010 |
|---|---|---|---|---|
| Total revenue | $301.0 million | $269.6 million | $911.5 million | $819.6 million |
| Gross profit | $158.7 million | $142.2 million | $487.6 million | $433.9 million |
| Gross margin | 52.7% | 52.7% | 53.5% | 52.9% |
| Operating income | $56.1 million | $49.8 million | $180.9 million | $153.1 million |
| Operating margin | 18.6% | 18.5% | 19.9% | 18.7% |
| Net income attributable to IDEXX | $38.5 million | $34.7 million | $123.8 million | $104.9 million |
| Diluted EPS | $0.66 | $0.59 | $2.11 | $1.76 |
| Cash flow from operations | Not separately reported | Not separately reported | $163.5 million | $130.0 million |
Q3 revenue increased 11.6%, operating income increased 12.6%, and diluted EPS increased 11.9%. For the first nine months, revenue increased 11.2%, operating income increased 18.2%, net income attributable to IDEXX increased 18.0%, and diluted EPS increased 19.9%.
- Reported nine-month organic revenue growth was 8.0%, excluding currency and acquisitions; Q3 organic growth was also 8.0%.
- Nine-month CAG revenue increased 10.6% to $748.4 million, including 7.6% organic growth. LPD revenue increased 23.7%, Water increased 8.3%, and Other increased 6.6%.
- Cash and cash equivalents were $181.5 million at September 30, 2011, compared with $156.9 million at December 31, 2010. Working capital was $174.4 million.
- Capital expenditures were $39.9 million through nine months, and management anticipated approximately $55 million of 2011 capital expenditures.
- Debt included $154.0 million outstanding under the revolving credit facility, $0.9 million of current long-term debt, and $2.7 million of long-term debt. Remaining availability under the $300 million facility was $145.0 million after the letter-of-credit reduction.
- The company repurchased 2.2 million shares for $166.0 million during the first nine months and authorized an additional four million shares for repurchase in October 2011.
Material changes versus the prior comparable period
- Growth was led by CAG instruments and consumables, reference laboratory services, and newer Catalyst Dx and ProCyte Dx products. Higher testing volumes and customer-acquisition programs supported reference laboratory growth.
- Q3 CAG organic growth was 8.0%; instruments and consumables grew organically 9.0%, reference laboratory services 9.8%, and practice management systems and digital radiography 11.4%. Rapid assay products declined organically 0.1%, partly because of distributor inventory changes.
- LPD benefited from higher bovine testing volumes, including German government tenders, but European Union changes increasing the BSE testing age to 72 months reduced BSE testing demand.
- Nine-month gross margin improved 60 basis points, while Q3 gross margin was unchanged. CAG’s nine-month margin improved modestly; Water and Other margins declined, with freight, pricing, manufacturing costs, and product mix affecting results.
- Operating expenses grew more slowly than revenue for the nine-month period, while unallocated expenses declined from $12.4 million to $8.5 million. Factors included lower personnel-related costs, certain foreign-exchange gains, lower FTC-related professional fees, and the absence of a prior-year impairment charge.
- Interest expense increased to $2.4 million from $1.7 million for the first nine months. The July refinancing increased the applicable credit spread, and existing interest-rate swaps also contributed to higher expense.
- A September 2011 business acquisition cost $3.2 million, with most of the purchase price allocated to goodwill and intangible assets. The acquisition was assigned to CAG and was not material enough to require pro forma disclosure.
Guidance, outlook, commentary, risks, and unusual items
- Management did not provide explicit full-year revenue or EPS guidance in the filing. It expected 2011 capital expenditures of approximately $55 million and expected interest expense to remain higher than in 2010 for the remainder of the year.
- Management believed cash, operating cash flow, and available credit were sufficient for operations, capital requirements, and strategic growth over the next twelve months and in the long term under the current business plan.
- The company refinanced its unsecured revolving facility in July 2011, increasing capacity from $200 million to $300 million and extending maturity to July 25, 2016. The company was in compliance with its covenants, including a maximum consolidated leverage ratio of 3-to-1.
- The FTC is investigating whether IDEXX’s companion-animal pricing and marketing practices may constitute unfair competition, including exclusive dealing or tying arrangements. The U.K. Office of Fair Trading is conducting a related investigation. IDEXX is cooperating, but the timing and outcome are uncertain; no loss contingency was recorded because a loss was not probable or reasonably estimable.
- Key operating risks include weak economic conditions and veterinary visit trends, distributor purchasing patterns, competition, reliance on sole or single-source suppliers, biologic manufacturing complexity, regulatory approvals, foreign-currency exposure, changes in disease testing requirements, and reliance on major corporate veterinary customers.
- Approximately 42% of revenue came from customers outside the U.S. in both the quarter and nine months, increasing exposure to currency, geopolitical, regulatory, and international operating risks.
- The filing reports no material changes to previously disclosed market risks. Management concluded that disclosure controls and procedures were effective, with no material changes to internal control over financial reporting.
Important facts investors should verify
- Whether reported revenue growth persists after separating currency effects, acquisitions, distributor inventory movements, and customer-acquisition incentives.
- The durability of CAG instrument placements and resulting consumables, service, and laboratory-testing revenue, including the transition from VetTest to Catalyst Dx and adoption of ProCyte Dx.
- The effect of continued economic weakness, veterinary visit trends, pricing pressure, and distributor consolidation on end-user demand and margins.
- The outcome and potential financial or commercial consequences of the FTC and U.K. OFT investigations.
- Future interest expense, borrowing levels, covenant compliance, and remaining capacity under the revolving credit facility.
- Whether the elevated share-repurchase program remains appropriate relative to capital expenditures, acquisitions, liquidity, and debt.
- The effect of EU BSE testing changes and other shifts in disease-testing requirements on LPD revenue.
- Execution of the company’s approximately $55 million capital-expenditure plan and integration of the September 2011 acquisition.